Candel Therapeutics shares are trading higher on continued strength after the company on Thursday announced interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic prostate cancer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.